Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Ianalumab is named as an intervention in 16 current clinical trials in our USA, China, UK and India registers. 6 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Novartis Pharmaceuticals. The most-studied condition is Primary Immune Thrombocytopenia (ITP).

Trials by status

Recruiting638%
Active, closed1063%

Trials by phase

Phase 31169%
Phase 2531%

Clinical trials of Ianalumab

16 trials

Study	Phase	Status	Lead sponsor	Registers
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). NCT06133972 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 3	Recruiting	Novartis Pharmaceuticals	USA, India, China
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) NCT06711887 · ClinicalTrials.gov ↗ · Lupus Nephritis	Phase 3	Recruiting	Novartis Pharmaceuticals	USA, China
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden NCT07621809 · ClinicalTrials.gov ↗ · Sjögren´s Disease	Phase 3	Recruiting	Novartis Pharmaceuticals	USA
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis NCT06470048 · ClinicalTrials.gov ↗ · Diffuse Cutaneous Systemic Sclerosis	Phase 2	Recruiting	Novartis Pharmaceuticals	UK, USA, India, China
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab NCT07039422 · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia	Phase 2	Recruiting	Novartis Pharmaceuticals	UK, China
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) NCT07421167 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)	Phase 2	Recruiting	Novartis Pharmaceuticals	USA
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis NCT05126277 · ClinicalTrials.gov ↗ · Lupus Nephritis	Phase 3	Active, closed	Novartis Pharmaceuticals	UK, USA, India, China
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome NCT05349214 · ClinicalTrials.gov ↗ · Sjogren Syndrome	Phase 3	Active, closed	Novartis Pharmaceuticals	UK, USA, India, China
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) NCT05624749 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 3	Active, closed	Novartis Pharmaceuticals	UK, USA, India
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) NCT05639114 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 3	Active, closed	Novartis Pharmaceuticals	USA, China
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia NCT05648968 · ClinicalTrials.gov ↗ · Warm Autoimmune Hemolytic Anemia (wAIHA)	Phase 3	Active, closed	Novartis Pharmaceuticals	UK, USA, India, China
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids NCT05653219 · Primary Immune Thrombocytopenia	Phase 3	Active, closed	Novartis Pharmaceuticals	UK, USA, India, China
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) NCT05653349 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia (ITP)	Phase 3	Active, closed	Novartis Pharmaceuticals	UK, USA, India, China
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. NCT05985915 · Sjogrens Syndrome	Phase 3	Active, closed	Novartis Pharmaceuticals	UK, USA, India, China
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa NCT03827798 · Hidradenitis Suppurativa	Phase 2	Active, closed	Novartis Pharmaceuticals	USA
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies NCT05885555 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia (ITP)	Phase 2	Active, closed	Novartis Pharmaceuticals	UK, USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Ianalumab

12 conditions

Primary Immune Thrombocytopenia (ITP)3 Systemic Lupus Erythematosus3Primary Immune Thrombocytopenia2Lupus Nephritis2Sjogrens Syndrome1Warm Autoimmune Hemolytic Anemia1Warm Autoimmune Hemolytic Anemia (wAIHA)1Diffuse Cutaneous Systemic Sclerosis1Primary Evans Syndrome (ES)1Sjogren Syndrome1Hidradenitis Suppurativa1Sjögren´s Disease1

By country register

Register	Trials	Recruiting
Clinical trials in USA	15	5
Clinical trials in China	12	4
Clinical trials in UK	10	2
Clinical trials in India	9	2

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Ianalumab trials

How many clinical trials are testing Ianalumab?

16 current trials in our USA, China, UK and India registers name Ianalumab (also registered as VAY736) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Ianalumab trials recruiting patients?

Yes. 6 of the 16 trials are recruiting: 5 with sites in USA, 4 with sites in China, 2 with sites in UK and 2 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Ianalumab clinical trials?

The lead sponsor is Novartis Pharmaceuticals. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ianalumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ianalumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ianalumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Ianalumab clinical trials